AOD-9604

Beginner Protocol

Intermediate Protocol

Advanced Protocol

Reconstitution and handling notes

Stacking Notes

Additional Dosage Notes

AOD-9604's development and commercial trajectory are an instructive cautionary tale in peptide therapeutics: a mechanistically elegant preclinical hypothesis that did not replicate in humans, yet is still heavily marketed decades later on the strength of the preclinical-era narrative.

Preclinical Development (1990s-2000s): Frank Ng and colleagues (Howard Florey Institute / Monash University) showed that synthetic C-terminal fragments of hGH (the 176/177-191 region) reduced body-weight gain and increased lipolysis in rodent obesity models without the growth-promoting or glucose-intolerance effects of full-length hGH: orally dosed obese Zucker rats (Ng et al., 2000; PubMed 11146367) and ob/ob mice, in which AOD9604 increased fat oxidation and lipolysis yet did NOT bind the hGH receptor or drive cell proliferation (Heffernan et al., 2001; PubMed 11673763). A related mouse study linked the effect to increased 3-adrenergic-receptor expression while concluding the lipolytic action is not mediated directly through 3-AR (Heffernan et al., 2001; PubMed 11713213). These findings generated enthusiasm because they suggested the beneficial lipolytic effects of GH might be pharmacologically separable from its growth-promoting and diabetogenic effects.

Human Development (Metabolic Pharmaceuticals, early-mid 2000s): The sponsor advanced AOD-9604 into human trials for obesity. Sponsor-reported early studies described good tolerability, no IGF-1 elevation (consistent with the targeted mechanism), and no adverse effect on glucose tolerance. An earlier short study reportedly showed a weight-loss signal, but the larger/longer Phase 2 study did NOT demonstrate statistically significant weight loss versus placebo, and the obesity program was discontinued (~2007).

Critical sourcing caveat: These human obesity results were communicated through the sponsor and secondary/review literature - there is NO peer-reviewed, PubMed-indexed randomized controlled trial of AOD-9604 for weight loss (positive or negative). An earlier version of this page cited a 'Heffernan et al., 2008' 536-patient trial; no such study exists (the PMID used actually pointed to an unrelated dermatology paper), and that citation has been removed. The bottom line is unchanged and well-supported: AOD-9604 has no published human efficacy evidence for weight loss.

Consequences:

• Metabolic Pharmaceuticals (Australia) abandoned obesity development.
• The company attempted to reposition AOD-9604 for osteoarthritis / cartilage repair; these programs did not reach approval.
• AOD-9604 was never approved as a drug by the FDA, EMA, TGA (Australia's regulator), or any other major authority.

Post-Pharmaceutical Second Life:

GRAS Determination (2014): A self-affirmed "Generally Recognized as Safe" (GRAS) determination was made for AOD-9604 as a low-dose oral ingredient in foods and dietary supplements. It is essential to understand what GRAS means and does not mean:

• GRAS is a safety determination, not an efficacy determination.
• It is typically self-affirmed by the sponsor (a GRAS notice), not a positive FDA drug approval.
• GRAS does not establish that oral AOD-9604 produces any therapeutic effect.
• For a 16-amino-acid peptide with no specialized oral-absorption technology, oral bioavailability is expected to be near-zero - peptide bonds are cleaved by gastric acid and pancreatic proteases before absorption.
• The designation has been questioned by obesity researchers as creating a regulatory path for marketing a failed drug as a supplement.

Research-Peptide Marketing: Simultaneously, AOD-9604 became widely available through "research chemical" suppliers selling the peptide as an injectable product explicitly for research use (often with "not for human consumption" disclaimers). Marketing materials focus heavily on the preclinical rodent data and the GRAS status while typically omitting the human efficacy failure. Typical marketed protocols use 250-500 mcg subcutaneously daily, often in combination with Ipamorelin, CJC-1295, or MOTS-c.

Anecdotal and Observational Reports: Among fitness communities and peptide users, AOD-9604 produces mixed anecdotal reports. Because there is no controlled human efficacy data, these reports cannot be attributed to AOD-9604 specifically - they likely reflect concurrent lifestyle changes, other peptides in stacks, placebo effects, or regression to the mean.

No Published Human Replication: No peer-reviewed Phase 2 or Phase 3 trial has been published showing AOD-9604 efficacy for weight loss or body composition in humans.

Osteoarthritis / Cartilage Applications: The strongest joint-related evidence is preclinical: intra-articular AOD9604 (alone or combined with hyaluronic acid) enhanced cartilage regeneration in a collagenase-induced rabbit osteoarthritis model (Kwon & Park, 2015; PubMed 26275694). Published human evidence for osteoarthritis or cartilage repair is lacking and does not support the strong claims made in marketing materials for joint health.

Current Scientific Consensus: Among obesity physicians and endocrinologists, AOD-9604 is considered a failed drug candidate with no demonstrated human efficacy for weight loss despite an attractive preclinical rationale. The continued marketing of AOD-9604 as an effective fat-loss peptide is not supported by peer-reviewed clinical evidence. Patients interested in peptide-based fat loss should consider validated alternatives: Semaglutide, Tirzepatide, or oral Orforglipron for GLP-1-based weight loss; Tesamorelin for FDA-approved GHRH-based visceral fat reduction; or lifestyle interventions (diet, exercise) as primary strategies.

AOD-9604's side effect profile is largely benign based on available data, reflecting its failure to produce significant physiological effects - a compound that does little tends to cause few side effects.

From the developer's human trials (sponsor-reported; no peer-reviewed RCT published): Across the doses studied, AOD-9604 was well tolerated:

• Injection site reactions: mild, typical for any subcutaneous peptide (mild redness, minor bruising, transient pain)
• Headache: occasional
• Fatigue: occasional
• Minor gastrointestinal symptoms: uncommon
• No serious adverse events attributable to AOD-9604
• No clinically significant changes in laboratory parameters
• No cardiac rhythm disturbances
• No effects on glucose tolerance or insulin sensitivity
• No increase in IGF-1 levels (confirming the targeted selectivity)
• No adverse effects on thyroid function
• No immunogenicity issues (no significant anti-drug antibody formation)

Theoretical Concerns:

• Peptide immunogenicity: Any injected peptide carries theoretical risk of immune response; this was not observed in the available AOD-9604 human data
• Purity concerns for research peptide sourcing: Research-grade peptides sourced outside pharmaceutical supply chains may contain contaminants, incorrect peptide sequences, bacterial endotoxin from synthesis errors, or degraded product. Quality varies substantially across suppliers.
• Injection site complications: Infection, sterile abscess, or local reactions from improper injection technique or non-sterile reconstitution practices

Oral Supplement Form: For oral AOD-9604 in supplements (low dose under the GRAS framework):

• Reported side effects: minimal to none in marketed use
• Likely reason: negligible systemic absorption of the peptide through the oral route
• Theoretical concern: any supplement may contain undisclosed adulterants

Compared to Other Peptides:

• AOD-9604 side effect profile is generally milder than:
  • GLP-1 agonists (nausea, vomiting, GI)
  • Growth hormone secretagogues (water retention, carpal tunnel, glucose effects at higher doses)
  • Melanotan-family peptides (nausea, flushing, erections)
• This mild profile partly reflects AOD-9604's limited physiological activity

Pregnancy and Lactation:

• Not recommended; insufficient data
• No adequate pregnancy studies in humans
• Avoid during pregnancy and breastfeeding as standard precaution for any peptide without established safety data

Long-Term Safety:

• Long-term (>6 month) controlled human safety data are not available
• Theoretical long-term concerns include immunogenicity with repeated administration over years (not demonstrated in available data)
• Effects on cardiovascular outcomes, cancer incidence, or metabolic health over decades are unknown

Contraindications Specific to AOD-9604:

• Prior hypersensitivity to AOD-9604 or peptide components
• Known active growth hormone-responsive neoplasms (theoretical caution even though AOD-9604 doesn't activate the GH receptor for growth - conservative practice)
• Acute critical illness (analogous to hGH caution, though not mechanistically equivalent)

Who Should Avoid AOD-9604:

• Patients seeking evidence-based weight loss interventions (choose GLP-1 class drugs instead)
• Patients with severe adipose-related conditions requiring effective treatment (AOD-9604 is not expected to produce meaningful clinical effects)
• Patients on limited budgets (money is better spent on validated interventions)
• Patients who have tried AOD-9604 for 12+ weeks without noticeable effect (continuing is unlikely to help)

Harm Reduction for Users Who Proceed:

• Use sterile technique: alcohol swab, fresh needle each injection, bacteriostatic water for reconstitution
• Source from reputable vendors with third-party testing / certificates of analysis
• Inject subcutaneously in abdominal or thigh fat with a 27-30G insulin syringe
• Rotate injection sites to prevent lipoatrophy
• Store reconstituted product refrigerated, use within 2-4 weeks
• Discontinue if any unusual symptoms develop
• Recognize that observed "results" may be largely attributable to concurrent lifestyle changes

Key Honest Framing: AOD-9604 is not "dangerous" in the typical sense - it has a benign safety profile in the available data. But its primary risk is opportunity cost: patients who use AOD-9604 for weight loss and see no results may conclude "peptides don't work for me" or delay seeking evidence-based treatment. For a patient with clinically significant obesity, using AOD-9604 rather than FDA-approved therapies represents a real harm through delayed effective treatment, even if AOD-9604 itself causes no direct adverse effects.